Buckingham Asset Management LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,485 shares of the medical research company’s stock after selling 37 shares during the quarter. Buckingham Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $705,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Laurel Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 104.3% in the 1st quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. Stonebridge Financial Planning Group LLC bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $32,000. Ballast Advisors LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at about $35,000. Savior LLC bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $44,000. Finally, Lloyd Advisory Services LLC. bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $44,000. Institutional investors own 89.26% of the company’s stock.

In other news, CEO Marc N. Casper sold 30,000 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total transaction of $9,990,600.00. Following the completion of the transaction, the chief executive officer now directly owns 304,946 shares in the company, valued at approximately $101,553,116.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Mark Stevenson sold 25,000 shares of the business’s stock in a transaction on Friday, April 24th. The shares were sold at an average price of $328.03, for a total transaction of $8,200,750.00. Following the transaction, the chief operating officer now owns 73,538 shares of the company’s stock, valued at $24,122,670.14. The disclosure for this sale can be found here. 0.45% of the stock is currently owned by insiders.

Several brokerages recently weighed in on TMO. SVB Leerink raised their price target on shares of Thermo Fisher Scientific from $330.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, April 23rd. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $340.00 to $341.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 4th. BTIG Research lifted their target price on shares of Thermo Fisher Scientific from $342.00 to $372.00 and gave the stock an “in-line” rating in a research report on Friday, January 31st. Needham & Company LLC lifted their target price on shares of Thermo Fisher Scientific from $341.00 to $383.00 in a research report on Thursday, April 23rd. Finally, Argus reissued a “positive” rating and set a $370.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, February 24th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $347.21.

Thermo Fisher Scientific stock opened at $342.92 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $250.21 and a 1-year high of $346.89. The firm has a market capitalization of $133.20 billion, a price-to-earnings ratio of 37.60, a P/E/G ratio of 2.24 and a beta of 1.04. The company has a current ratio of 2.32, a quick ratio of 1.69 and a debt-to-equity ratio of 0.67. The firm has a 50 day simple moving average of $315.92 and a 200 day simple moving average of $315.91.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $2.94 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.15. Thermo Fisher Scientific had a net margin of 14.31% and a return on equity of 17.25%. The business had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6.18 billion. During the same period in the previous year, the business earned $2.81 EPS. Thermo Fisher Scientific’s revenue was up 1.7% compared to the same quarter last year. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 11.88 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Beige Book

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.